The psychological impact of screening with a multicancer early detection test

Mené sur 6 621 personnes en bonne santé ayant réalisé un test de détection multicancer (durée de suivi : 12 mois), cet essai multicentrique évalue les effets psychosociaux rapportés par les patients après ce test (effet de la divulgation du résultat, symptômes d'anxiété générale, qualité de vie liée à la santé et satisfaction)

Résumé en anglais

Multicancer early detection tests (MCEDs) offer a tantalising opportunity to screen for several cancers, including cancers with poor prognosis for which we currently have no effective screening tests. A growing number of MCEDs exist at various stages of development, with a wide range of reported sensitivities and specificities. Some are already commercially available. A major source of debate relates to the level of evidence of benefit necessary to justify funders investing in MCEDs as part of population cancer screening. The NHS-Galleri trial will report on the incidence rate of detected stage 3 and stage 4 cancers in 2026, but evidence on the effect of MCEDs on cancer mortality is several years away.